Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Cancer Retrieve available abstracts of 92 articles: HTML format

Single Articles

April 2024
1. NIERENGARTEN MB
   Promising new treatment approaches for locally advanced cervical cancer.
   Cancer. 2024;130:1192.
   PubMed    
   
   
   
2. ERICKSON BK, Slomovitz B, Powell M, Eskander RN, et al
   Top advances of the year: Uterine cancer.
   Cancer. 2024 Apr 15. doi: 10.1002/cncr.35321.
   PubMed     Abstract available
   
   
   March 2024
3. MEGHANI K, Puri P, Bazzett-Matabele L, Vuylsteke P, et al
   Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
   Cancer. 2024 Mar 26. doi: 10.1002/cncr.35289.
   PubMed     Abstract available
   
   
   
4. LEE H, Baeker Bispo J, Pal Choudhury P, Wiese D, et al
   Factors contributing to differences in cervical cancer screening in rural and urban community health centers.
   Cancer. 2024 Mar 25. doi: 10.1002/cncr.35265.
   PubMed     Abstract available
   
   
   
5. MICHEL AD, Fontenot HB, Fuzzell L, Brownstein NC, et al
   Attitudes toward the American Cancer Society's 2020 cervical cancer screening guidelines: A qualitative study of a national sample of US clinicians.
   Cancer. 2024 Mar 4. doi: 10.1002/cncr.35269.
   PubMed     Abstract available
   
   
   February 2024
6. LIU YL, Weigelt B
   A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
   Cancer. 2024 Feb 29. doi: 10.1002/cncr.35267.
   PubMed     Abstract available
   
   
   
7. YANG EH, Strohl HB, Su HI
   Fertility preservation before and after cancer treatment in children, adolescents, and young adults.
   Cancer. 2024;130:344-355.
   PubMed     Abstract available
   
   
   January 2024
8. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
   Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
   Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
   PubMed     Abstract available
   
   
   
9. FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al
   When the unimaginable happens: Lung cancer diagnosis during pregnancy.
   Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227.
   PubMed    
   
   
   
10. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed     Abstract available
    
    
    
11. 
    New test for detecting cervical adenocarcinoma.
    Cancer. 2024;130:10.
    PubMed    
    
    
    
12. BYTNAR JA, McGlynn KA, Nealeigh MD, Shriver CD, et al
    Cancer incidence in the US military: An updated analysis.
    Cancer. 2024;130:96-106.
    PubMed     Abstract available
    
    
    December 2023
13. RIMEL BJ, Enserro D, Bender DP, Jackson CG, et al
    NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Cancer. 2023 Dec 21. doi: 10.1002/cncr.35151.
    PubMed     Abstract available
    
    
    
14. LUMISH MA, Kohn EC, Tew WP
    Top advances of the year: Ovarian cancer.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35135.
    PubMed     Abstract available
    
    
    November 2023
15. HINCHCLIFF EM, Knisely A, Adjei N, Fellman B, et al
    Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Cancer. 2023 Nov 27. doi: 10.1002/cncr.35126.
    PubMed     Abstract available
    
    
    
16. 
    HPV testing in older women may improve cervical cancer prevention.
    Cancer. 2023;129:3518.
    PubMed    
    
    
    October 2023
17. GRITHER WR, Hagemann IS, Powell MA, Mullen MM, et al
    Attack of the clones: Unveiling subclonal/heterogenous mismatch repair (MMR)/microsatellite instability (MSI) status in endometrial cancer (EC).
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35067.
    PubMed    
    
    
    
18. 
    Retraction: Yanjing Wu, Shupeng Liu, Hong Xin, Jing Jiang, Edward Younglai, Shuhan Sun, and Huilan Wang. Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 2011;117:3989-3998.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35092.
    PubMed    
    
    
    
19. LIU YL, Gordhandas S, Arora K, Rios-Doria E, et al
    Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
    Cancer. 2023 Oct 27. doi: 10.1002/cncr.35071.
    PubMed     Abstract available
    
    
    
20. SOROURI K, Sella T, Rosenberg SM, Loucks M, et al
    Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35066.
    PubMed     Abstract available
    
    
    
21. KNISELY A, Ahmed J, Stephen B, Piha-Paul SA, et al
    Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
    Cancer. 2023 Oct 21. doi: 10.1002/cncr.35063.
    PubMed     Abstract available
    
    
    
22. FLOREZ N, Kiel L, Meza K, Wei Z, et al
    Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.
    PubMed     Abstract available
    
    
    
23. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    PubMed     Abstract available
    
    
    September 2023
24. RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al
    Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030.
    PubMed     Abstract available
    
    
    
25. NIERENGARTEN MB
    New standard of care for platinum-resistant ovarian cancer.
    Cancer. 2023;129:2601-2602.
    PubMed    
    
    
    
26. NIERENGARTEN MB
    Combination therapy may create a practice change for advanced or recurrent endometrial cancer: Two new studies show the value of adding immunotherapy to standardof-care chemotherapy to improve progression-free survival.
    Cancer. 2023;129:2600-2601.
    PubMed    
    
    
    
27. VADAPARAMPIL ST, Fuzzell LN, Brownstein NC, Fontenot HB, et al
    A cross-sectional survey examining clinician characteristics, practices, and attitudes associated with adoption of the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines.
    Cancer. 2023;129:2671-2684.
    PubMed     Abstract available
    
    
    
28. NIERENGARTEN MB
    Not removing ovaries during benign hysterectomy: Benefits may outweigh risks.
    Cancer. 2023;129:2602.
    PubMed    
    
    
    
29. MACKINNON KM, Risica PM, von Ash T, Scharf AL, et al
    Barriers and motivators to women's cancer screening: A qualitative study of a sample of diverse women.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    July 2023
30. WHITE VM, Alexiadis M, Eroh KD, Ackermann MK, et al
    How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.
    Cancer. 2023;129:2224-2234.
    PubMed     Abstract available
    
    
    
31. PRINTZ C
    Yale study finds Black patients are more likely to experience uterine cancer testing delays.
    Cancer. 2023;129:2115-2116.
    PubMed    
    
    
    June 2023
32. GRISHAM RN, Manning-Geist BL, Chui MH
    The highs and lows of serous ovarian cancer.
    Cancer. 2023 Jun 27. doi: 10.1002/cncr.34903.
    PubMed     Abstract available
    
    
    
33. MEDINA HN, Penedo FJ, Joachim C, Deloumeaux J, et al
    Endometrial cancer risk and trends among distinct African descent populations.
    Cancer. 2023 Jun 26. doi: 10.1002/cncr.34789.
    PubMed     Abstract available
    
    
    
34. FRANCO EL
    The time has come to implement primary human papillomavirus screening for cervical cancer in the United States.
    Cancer. 2023 Jun 22. doi: 10.1002/cncr.34899.
    PubMed    
    
    
    
35. MIRZA MR, Gonzalez-Martin A, Graybill WS, O'Malley DM, et al
    Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Cancer. 2023;129:1846-1855.
    PubMed     Abstract available
    
    
    May 2023
36. THOMAS TH, Bender C, Donovan HS, Murray PJ, et al
    The feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game for women with advanced breast or gynecologic cancer.
    Cancer. 2023 May 27. doi: 10.1002/cncr.34887.
    PubMed     Abstract available
    
    
    
37. SPENCER JC, Noel L, Shokar NK, Pignone MP, et al
    Understanding the role of access in Hispanic cancer screening disparities.
    Cancer. 2023;129:1569-1578.
    PubMed     Abstract available
    
    
    
38. KINDLER HL, Yoo HK, Hettle R, Cui KY, et al
    Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Cancer. 2023;129:1411-1418.
    PubMed     Abstract available
    
    
    April 2023
39. BEN-ARYE E, Lavie O, Segev Y, Samuels N, et al
    Reply to "Assessing the impacts of integrative therapies on pain and anxiety after gynecological oncology surgery".
    Cancer. 2023 Apr 13. doi: 10.1002/cncr.34803.
    PubMed    
    
    
    
40. XUE FS, Yang WH, Li CW
    Assessing the impacts of integrative therapies on pain and anxiety after gynecological oncology surgery.
    Cancer. 2023 Apr 13. doi: 10.1002/cncr.34805.
    PubMed    
    
    
    
41. AYALA-PEACOCK DN, Chino JP
    Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?
    Cancer. 2023 Apr 12. doi: 10.1002/cncr.34769.
    PubMed    
    
    
    
42. WANG S, Liu J, Lei K, Jia Y, et al
    Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-cen
    Cancer. 2023 Apr 12. doi: 10.1002/cncr.34771.
    PubMed     Abstract available
    
    
    
43. NIERENGARTEN MB
    Balancing the benefits and harms of cervical cancer screening in older women.
    Cancer. 2023;129:979-980.
    PubMed    
    
    
    March 2023
44. MANNING-GEIST BL, Kahn RM, Nemirovsky D, Girshman J, et al
    Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34753.
    PubMed     Abstract available
    
    
    
45. FOSTER KI, Shaw KRM, Jin J, Westin SN, et al
    Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Cancer. 2023 Mar 17. doi: 10.1002/cncr.34724.
    PubMed     Abstract available
    
    
    
46. METCALFE KA, Gronwald J, Tung NM, McCuaig JM, et al
    The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    Cancer. 2023;129:901-907.
    PubMed     Abstract available
    
    
    
47. CHINO JP, Moss HA, Swartz JJ, Gray BA, et al
    Care of the pregnant patient with cancer should include unfettered access to abortion.
    Cancer. 2023 Mar 12. doi: 10.1002/cncr.34686.
    PubMed    
    
    
    
48. NGUYEN T, Bhosale PR, Cassia L, Surabhi V, et al
    Malignancy in pregnancy: Multimodality imaging and treatment.
    Cancer. 2023 Mar 12. doi: 10.1002/cncr.34688.
    PubMed     Abstract available
    
    
    
49. HENDRIKSE CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, et al
    Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34661.
    PubMed     Abstract available
    
    
    
50. GRISHAM RN, Manning-Geist BL, Chui MH
    Beyond the estrogen receptor: In search of predictive biomarkers for low-grade serous ovarian cancer.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34658.
    PubMed    
    
    
    
51. NIERENGARTEN MB
    FDA grants accelerated approval for targeted therapy for platinum-resistant gynecologic cancers.
    Cancer. 2023;129:656.
    PubMed    
    
    
    February 2023
52. HYDE ET, LaCroix AZ, Evenson KR, Howard AG, et al
    Accelerometer-measured physical activity and postmenopausal breast cancer incidence in the Women's Health Accelerometry Collaboration.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34699.
    PubMed     Abstract available
    
    
    January 2023
53. BEN-ARYE E, Segev Y, Galil G, Marom I, et al
    Acupuncture during gynecological oncology surgery: A randomized controlled trial assessing the impact of integrative therapies on perioperative pain and anxiety.
    Cancer. 2023 Jan 17. doi: 10.1002/cncr.34542.
    PubMed     Abstract available
    
    
    
54. PODWIKA SE, Duska LR
    Top advances of the year: Cervical cancer.
    Cancer. 2023 Jan 7. doi: 10.1002/cncr.34617.
    PubMed     Abstract available
    
    
    December 2022
55. KANG EY, Weir A, Meagher NS, Farrington K, et al
    CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582.
    PubMed     Abstract available
    
    
    October 2022
56. LUTGENDORF SK, Thaker PH, Goodheart MJ, Arevalo JMG, et al
    Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.
    Cancer. 2022 Oct 17. doi: 10.1002/cncr.34496.
    PubMed     Abstract available
    
    
    
57. DUSKA LR
    Overcoming disparities to improve cancer care: The story of cervical cancer.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34488.
    PubMed     Abstract available
    
    
    
58. VIKRAMAN SM, Khanna D, Dandpat A
    Cervical cancer elimination in indian context: Moving from barriers to facilitators.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34486.
    PubMed     Abstract available
    
    
    
59. RIMEL BJ, Kunos CA, Macioce N, Temkin SM, et al
    Current gaps and opportunities in screening, prevention, and treatment of cervical cancer.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34487.
    PubMed     Abstract available
    
    
    
60. MARKOVINA S, Rendle KA, Cohen AC, Kuroki LM, et al
    Improving cervical cancer survival-A multifaceted strategy to sustain progress for this global problem.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34485.
    PubMed     Abstract available
    
    
    
61. O'ROURKE K
    First person profile: Robert C. Bast Jr MD: As an ovarian cancer expert, Dr Bast has made history by identifying cancer antigen 125, and he has shared his knowledge by mentoring the next generation of physicians: As an ovarian cancer expert, Dr Bast h
    Cancer. 2022;128:3431-3432.
    PubMed    
    
    
    August 2022
62. MCDANIELS-DAVIDSON C, Feng CH, Martinez ME, Canchola AJ, et al
    Improved survival in cervical cancer patients receiving care at National Cancer Institute-designated cancer centers.
    Cancer. 2022 Aug 2. doi: 10.1002/cncr.34404.
    PubMed     Abstract available
    
    
    July 2022
63. MOUKARZEL LA, Ferrando L, Stylianou A, Lobaugh S, et al
    Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer.
    Cancer. 2022 Jul 6. doi: 10.1002/cncr.34356.
    PubMed     Abstract available
    
    
    June 2022
64. RAUH-HAIN JA, Zubizarreta J, Nitecki R, Melamed A, et al
    Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study.
    Cancer. 2022 Jun 29. doi: 10.1002/cncr.34371.
    PubMed     Abstract available
    
    
    
65. MARTH C, Abreu MH, Andersen KK, Aro KM, et al
    Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    Cancer. 2022 Jun 17. doi: 10.1002/cncr.34350.
    PubMed     Abstract available
    
    
    
66. JAMIESON A, Barroilhet LM, McAlpine JN
    Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape.
    Cancer. 2022 Jun 3. doi: 10.1002/cncr.34328.
    PubMed     Abstract available
    
    
    
67. O'ROURKE K
    Cemiplimab shines for recurrent cervical cancer.
    Cancer. 2022;128:2050-2051.
    PubMed    
    
    
    
68. JOUNG RH, Nelson H, Mullett TW, Kurtzman SH, et al
    A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Cancer. 2022;128:2119-2125.
    PubMed     Abstract available
    
    
    May 2022
69. NERO C, Pasciuto T, Cappuccio S, Corrado G, et al
    Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
    Cancer. 2022 May 26. doi: 10.1002/cncr.34331.
    PubMed     Abstract available
    
    
    
70. STENZEL AE, Bustamante G, Sarkin CA, Harripersaud K, et al
    The intersection of sexual orientation with race and ethnicity in cervical cancer screening.
    Cancer. 2022 May 16. doi: 10.1002/cncr.34213.
    PubMed     Abstract available
    
    
    
71. O'ROURKE K
    Pembrolizumab is effective for endometrial cancer.
    Cancer. 2022;128:1886-1887.
    PubMed    
    
    
    April 2022
72. O'ROURKE K
    Better HPV vaccination and cervical cancer screening needed.
    Cancer. 2022;128:1559.
    PubMed    
    
    
    February 2022
73. EKANAYAKE WEERAMANGE C, Shu D, Tang KD, Batra J, et al
    Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer.
    Cancer. 2022 Feb 17. doi: 10.1002/cncr.34148.
    PubMed     Abstract available
    
    
    
74. LU E, Hatchell KE, Nielsen SM, Esplin ED, et al
    Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
    Cancer. 2022;128:675-684.
    PubMed     Abstract available
    
    
    January 2022
75. HENDERSON TO, Fowler BW, Hamann HA, Nathan PC, et al
    Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor.
    Cancer. 2022;128:373-382.
    PubMed     Abstract available
    
    
    
76. ARUN BK, Peterson SK, Sweeney LE, Bluebond RD, et al
    Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Cancer. 2022;128:94-102.
    PubMed     Abstract available
    
    
    December 2021
77. MCBRIDE CM, Pathak S, Johnson CE, Alberg AJ, et al
    Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    Cancer. 2021 Dec 9. doi: 10.1002/cncr.34053.
    PubMed     Abstract available
    
    
    
78. BELLONE S, Roque DM, Siegel ER, Buza N, et al
    A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Cancer. 2021 Dec 7. doi: 10.1002/cncr.34025.
    PubMed     Abstract available
    
    
    
79. ANTILL Y, Buchanan DD, Scott CL
    Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer.
    Cancer. 2021 Dec 7. doi: 10.1002/cncr.34024.
    PubMed     Abstract available
    
    
    
80. MOMTAZ P, O'Connor CA, Chou JF, Capanu M, et al
    Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Cancer. 2021;127:4393-4402.
    PubMed     Abstract available
    
    
    November 2021
81. PEI J, Li M, Wu C, Xu M, et al
    Worldwide trends in cervical cancer incidence and mortality.
    Cancer. 2021 Nov 24. doi: 10.1002/cncr.34029.
    PubMed    
    
    
    
82. LIN S, Gao K, Jin M
    Reply to Worldwide trends in cervical cancer incidence and mortality.
    Cancer. 2021 Nov 24. doi: 10.1002/cncr.34031.
    PubMed    
    
    
    
83. TEMKIN SM, Smeltzer MP, Dawkins MD, Boehmer LM, et al
    Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
    Cancer. 2021 Nov 17. doi: 10.1002/cncr.34023.
    PubMed     Abstract available
    
    
    
84. DESAI S, Zhu MJ, Lapidos-Salaiz I
    Cervical cancer prevention: Human papillomavirus testing as primary screening.
    Cancer. 2021 Nov 12. doi: 10.1002/cncr.34006.
    PubMed     Abstract available
    
    
    October 2021
85. DIN HN, Strong D, Singh-Carlson S, Corliss HL, et al
    Association between pregnancy intention and preconception health behaviors.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33958.
    PubMed     Abstract available
    
    
    
86. BRANDT HM, Kepka D, Kirchhoff AC, Daniel CL, et al
    Human papillomavirus (HPV) vaccination is cancer prevention for childhood cancer survivors.
    Cancer. 2021 Oct 4. doi: 10.1002/cncr.33920.
    PubMed    
    
    
    
87. NIERENGARTEN MB
    Rucaparib is a safe and effective maintenance therapy for advanced pancreatic cancer.
    Cancer. 2021;127:3498.
    PubMed    
    
    
    
88. PINATTI LM, Gu W, Wang Y, Elhossiny A, et al
    SearcHPV: A novel approach to identify and assemble human papillomavirus-host genomic integration events in cancer.
    Cancer. 2021;127:3531-3540.
    PubMed     Abstract available
    
    
    September 2021
89. KOTSOPOULOS J, Kim SJ, Armel S, Bordeleau L, et al
    An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    Cancer. 2021;127:3183-3193.
    PubMed     Abstract available
    
    
    August 2021
90. SCHAEFER IM, Lundberg MZ, Demicco EG, Przybyl J, et al
    Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Cancer. 2021;127:2666-2673.
    PubMed     Abstract available
    
    
    June 2021
91. MAKHNOON S, Tran G, Levin B, Mattie KD, et al
    Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33668.
    PubMed     Abstract available
    
    
    March 2021
92. BALACHANDRA S, Kusin SB, Lee R, Blackwell JM, et al
    Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.
    Cancer. 2021;127:850-864.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.